Cargando…
Neuroendocrine metastasis to the thyroid from unknown primary and extrathyroidal disease response to peptide receptor radionuclide therapy
Neuroendocrine tumor (NET) metastasis to the thyroid is rare, and its presentation as the first manifestation of primary malignancy elsewhere is even more uncommon. We present a case of a 41-year-old female who underwent biopsy of enlarging thyroid nodules with findings suspicious for medullary thyr...
Autores principales: | Khessib, Tasnim, Khessib, Samy, Berry, Gerald, Aparici, Mari |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480434/ https://www.ncbi.nlm.nih.gov/pubmed/37680654 http://dx.doi.org/10.1016/j.radcr.2023.07.044 |
Ejemplares similares
-
Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report
por: Zhang, Vivian, et al.
Publicado: (2023) -
The Definition of Minimal Extrathyroid Extension in Thyroid Pathology by Analyzing Sizable Intra- and Extrathyroid Blood Vessels
por: Jeon, Hyae Min, et al.
Publicado: (2012) -
Peptide Receptor Radionuclide Therapy in Thyroid Cancer
por: Gubbi, Sriram, et al.
Publicado: (2022) -
Management of Graves Thyroidal and Extrathyroidal Disease: An Update
por: Kahaly, George J
Publicado: (2020) -
Value of Peptide Receptor Radionuclide Therapy as Neoadjuvant Treatment in the Management of Primary Inoperable Neuroendocrine Tumors
por: Opalińska, Marta, et al.
Publicado: (2021)